Topical haemoglobin spray promises to speed healing and reduce pain while contributing to reduced costs to the NHS
• Granulox® haemoglobin spray included in NHS tariff part IX as of 1st October 2016
• UK real world studies confirm faster healing as well as cost effectiveness
• Potential to save £1,000’s per patient
• Infirst planning to drive geographic expansion of Granulox to USA
29 September 2016 – Infirst Healthcare* announces its innovative haemoglobin spray Granulox, for the treatment of chronic wounds, has been added to the NHS Drug Tariff Part IX, establishing a new Haemoglobin category. The first treatment of its kind, Granulox will be available on prescription across the UK from 1st October 2016.
Currently up to 200,000 patients in the UK are living with non-healing wounds[i],[ii] such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and post-surgical wounds. Treating these patients costs the NHS between £2.3-3.1 billion a year2 in associated costs including nursing time, dressings, hospital admissions, pain relief and too often amputations.
“This is very good news for UK patients who suffer from debilitating chronic wounds that severely affect their physical and emotional well-being,” says Manfred Scheske, CEO of Infirst Healthcare. “It is also good news for healthcare professionals and for the NHS to add a novel treatment option to standard therapy which promises significant patient benefits as well as cost effectiveness. As a growing healthcare company championing innovative products, we have been dedicated to gaining healthcare providers’ recognition for Granulox and are determined to make Granulox available to more geographies outside the UK including the USA.”
Granulox increases levels of oxygen at the wound bed, speeding up the rate of healing[iii] in wounds such as venous leg ulcers, by 75 percent compared to standard care[iv]. The treatment also reduces pain by an average of 68 percent within two weeks4.
Independent clinical studies have shown that, when added to standard care, Granulox could save the NHS an average of £2,330 for every diabetic foot ulcer patient and £1,469 for every chronic wound patient after six months[v]. The clinical efficacy and cost analysis data have also been reviewed and verified by the Scottish Health Technologies Group (SHTG), part of NHS Scotland, which recently published its summary of evidence in support of Granulox. It stated that the addition of “Granulox was found to be more effective and less costly than standard care alone”6.
For all media enquiries, please contact:
Hume Brophy
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 207 862 6399
infirst@humebrophy.com
About Chronic Wounds: Chronic wounds do not heal in an orderly set of stages and in a predictable amount of time (within 3 months), the way most wounds do. The aetiology of chronic wounds is diverse, but more than 80% are associated with venous insufficiency, high blood pressure or diabeties mellitus, leading to inadequate oxygen supply via the vascular system[vi].
About Infirst Healthcare:
infirst Healthcare is a UK-based healthcare company which operates in the US and the UK. Its developments aim to build on the trust and safety of well-known drugs and to develop formulations which result in a genuinely perceived difference in performance. The ultimate goal is improved and highly effective health management at an early intervention stage, involving patients, clinicians and payers as well as pharmacists.
